Search Results Label57 results found
Seqirus has been on the front line of pandemic preparedness for more than a century. Learn more about our rapid vaccine production capabilities.
Seqirus Announces Investment in Next-Generation Influenza Vaccine Technology, Self-Amplifying Messenger RNA (sa-mRNA)
Seqirus appoints Roberta Duncan as new program lead to drive technology advancement. Accelerates development of sa-mRNA vaccine candidates for seasonal and pandemic influenza.
Seqirus Presents New Data at ESWI 2020 Demonstrating Safety and Immunogenicity of Adjuvanted, Cell-Based Pandemic Influenza A (H5N1) Vaccine
Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.
Seqirus announced today that the accelerated development of cell-based manufacturing technology at its manufacturing facility in Holly Springs, North Carolina, has delivered a four-fold increase in seasonal influenza vaccine output in just two years, strengthening the United States’ capacity to respond to pandemic threats.
Seqirus Presents New Safety Data Demonstrating Safety of Cell-Based Seasonal Influenza Vaccine on Pregnancy Outcomes
Findings from a new observational safety study conducted in the U.S. found no unexpected adverse pregnancy outcomes in pregnant people who were vaccinated with the cell-based quadrivalent seasonal influenza vaccine during pregnancy.
The company is prepared to meet the record levels of demand seen during the 2020/21 influenza season amidst the ongoing COVID-19 pandemic
New Phase 3 Clinical Data Supporting Use of Cell-Based Seasonal Influenza Vaccine in Children Six Months Through <4 Years of Age
Seqirus, as a member of the CSL group, is bound by CSL's Code of Responsible Business Practice. Access our annual financial and diversity disclosures.